Volume 1,Issue 3
Received: 31 May 2017; Published: 28 September 2017; doi: 10.21926/obm.transplant.1703005
Cardiac allograft vasculopathy(CAV) is one of the leading causes of death following the first 5 years after orthotopic heart transplantation(OHT) along with late graft failure( likely secondary to undiagnosed CAV. Currently there is no single medical treatment available for this condition except modification of risk factors and immunosuppression. Retrasplantation remains the hope for this entity with some limitations.
Received: 16 July 2017; Published: 12 September 2017; doi: 10.21926/obm.transplant.1703004
The risk for developing a variety of malignancies is significantly elevated in the setting of lung transplantation. Malignancy remains among the three major causes of death in post-transplant recipients, and the relatively high risk of cancer development as well as metastatic aggression pose special threats to this population due to the need for continued immunosuppression. A variety of risks such as tobacco use and inflammatory lung diseases that led to the lung pathology prompting lung transpl [...]